Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52)

(3)
Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52) image
ISBN-10:

0120329549

ISBN-13:

9780120329540

Author(s): Young, Andrew
Edition: 1
Released: Dec 26, 2005
Publisher: Academic Press
Format: Hardcover, 360 pages

Description:

Amylin deciphers amylin's physiology and reveals previously unrecognized mechanisms fundamental to control body weight and fuel homeostasis. This book also discusses therapeutic utility of amylin as the first new medicine to treat diabetes since insulin.Provides a current comprehensive treatment of amylin the hormoneIdentifies the majority of amylin's physiologic functions

Best prices to buy, sell, or rent ISBN 9780120329540




Related Books

Frequently Asked Questions about Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52)

You can buy the Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52) book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $52.99 on Amazon and is available from 6 sellers at the moment.

If you’re interested in selling back the Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52) book, the best buyback offer comes from and is $ for the book in good condition.

The Amylin: Physiology and Pharmacology (Volume 52) (Advances in Pharmacology, Volume 52) book is in very low demand now as the rank for the book is 11,930,064 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.

Not enough insights yet.